Acrivon Therapeutics, Inc. (ACRV) is a Watertown, Massachusetts-based clinical-stage biopharmaceutical company developing precision oncology and immunology medicines through its AI-driven AP3 phosphoproteomics platform. Its lead asset, ACR-368, targets CHK1/CHK2 in endometrial cancer, while ACR-2316 is a first-in-class WEE1/PKMYT1 inhibitor in Phase 1/2 development. In today's session, ACRV shares fell 6.41% to $1.46, compared with the previous close of $1.56, confirming a downward move. The stock traded as low as $1.40 before recovering modestly. No verified company-specific catalyst was found for the decline; the pullback most plausibly reflects profit-taking after Wednesday's sharp advance and caution ahead of a key data readout.
No verified news or fundamental catalyst found for today's decline: Acrivon issued no press release, filed no material current report, and drew no disclosed analyst rating change during the session. The most consistent explanation is technical profit-taking after the stock's 9.09% jump on November 18, when shares closed at $1.56 on roughly 351,000 shares — well above its typical turnover. That rally had no accompanying announcement either, and it unfolded into an event-heavy calendar featuring a late-breaking oral plenary presentation of ACR-2316 dose-escalation results on November 20.
Positioning around binary clinical events is a recurring pattern in micro-cap biotech. Traders who bought the pre-event drift often reduce exposure before the data lands, particularly when the underlying catalyst carries the entire investment thesis. Today's session is consistent with that behavior: the stock opened near $1.59, drifted to $1.40 by late morning, and stabilized in the mid-$1.40s.
The broader setup remains defined by two verified developments from earlier in the week. On November 16, Acrivon reported third-quarter results with a net loss of $17.9 million, or $0.42 per share, slightly better than the $0.44 loss consensus, alongside research and development expense of $14.5 million and cash, equivalents, and investments of $77.8 million — a runway the company projects into the fourth quarter of 2027. The same day, it filed a universal shelf registration covering up to $300 million of securities, most of it carried forward from a prior shelf, alongside an at-the-market sales agreement capacity disclosed at roughly 11 million shares.
For a company with a market capitalization near $62 million, that financing capacity introduces a persistent dilution overhang. It does not by itself force selling, but it caps enthusiasm on rallies and makes shareholders quicker to lock in gains. The quarterly print also contained no incremental clinical update, leaving the stock without a fresh fundamental anchor between now and the ACR-368 interim analysis expected in the fourth quarter.
Volume has been moderate rather than capitulatory. Roughly 102,000 shares changed hands by midday in New York, tracking close to the stock's average full-day turnover of about 200,000 shares, with the heaviest blocks printing near the open and again around 11:35 a.m. ET. Selling was orderly and spread across the morning rather than concentrated in a single liquidation.
Technically, the move extends a downtrend. ACRV trades well below both its 50-day moving average near $1.82 and its 200-day average near $1.75, with the relative strength index in the mid-30s — a weak but not yet oversold posture. Today's $1.40 low sits above the 52-week floor of $1.27, an area that now marks the reference support level. The 52-week high of $3.56 underscores how far sentiment has traveled. The decline was concentrated in this single name rather than tracking broad index or large-cap biotech direction.
The score runs from 0 to 100, where 0 means no meaningful news and a move that is ordinary for the stock, and 100 means transformative news paired with an extreme, rare price move. Acrivon earns 17 out of 100.
Verified news was modest in scope: a routine shelf registration and in-line quarterly results, neither of which was published during today's session, and no disclosure at all on November 19. Judged against a company of this size, that is not material enough to explain a sharp decline. The price move, while noticeable, was only about 1.8 times the stock's typical absolute daily change of roughly 3.5%, and 13 of the past 69 sessions produced equal or larger swings. A stock that routinely moves 6% therefore scores low on both components.
Attention turns immediately to the November 20 late-breaking oral plenary at the 38th EORTC-NCI-AACR Symposium, where investigators will present ACR-2316 dose-escalation results. That dataset carries outsized weight for a company at this valuation. Beyond it, Acrivon has guided to a prespecified interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study in the fourth quarter of 2026, along with completion of enrollment in the registrational-intent Arm 3 or Arm 4. Management also targets FDA alignment on a Phase 2 eosinophilic esophagitis trial design for ACR-525 in the first quarter of 2027 and an IND filing for ACR-7280 in the first half of 2027.
The principal risks are clinical and financial: any disappointing data would hit a stock already trading below its long-term averages, and the disclosed shelf and ATM capacity means future capital raises remain a live possibility. Investors should also watch whether fourth-quarter cash burn accelerates as the ACR-368 and ACR-2316 programs scale.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in its Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page offers a useful starting point for comparing approaches rather than a single template. Reviewing the current leaders can help traders see how automated strategies are positioned in volatile, fast-moving names like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Oscillator for ACRV moved out of oversold territory on November 18, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 28 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 65 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 32 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.596). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology